MedTrace Logo

First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors

NCT02937116 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 233

Last updated 2022-10-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety, tolerability and efficacy of IBI308 monotherapy or in combination with chemotherapy in patients with certain types of advanced solid tumors. Another purpose is to determine the pharmacokinetics, pharmacodynamics and immunogenicity of IBI308.

Conditions

  • Cancer, Solid Tumor

Interventions

DRUG

IBI308

DRUG

IBI308\Cisplatinum\Pemetrexed

DRUG

IBI308\cisplatin\gemcitabine

DRUG

IBI308\oxaliplatin\capecitabine

DRUG

IBI308\etoposide\cisplatin

DRUG

IBI308\irinotecan\5-FU

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-19
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02937116 on ClinicalTrials.gov